Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.755 +0.635 (+15.41%)

Delayed Quote Updated: 12:02 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

23 24 Next >

Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board

May 24, 2024

Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur

From Recursion Pharmaceuticals

Via GlobeNewswire

2 Stocks That Could 10x by 2035 ↗

May 24, 2024

These stocks are very promising, but it's important to consider the downside, too.

Via The Motley Fool

Jim Cramer Offers His Take On Corning, Calls This Healthcare Stock A 'Terrific Spec' ↗

May 23, 2024

Jim Cramer says Corning has "not been able to generate the kind of return that I've wanted"; calls Recursion a "terrific spec"

Via Benzinga

A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In ↗

May 20, 2024

The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process...

Via Talk Markets

Topics Artificial Intelligence

Recursion Pharm Stock Sees Relative Strength Rating Rise To 84 ↗

May 14, 2024

On Tuesday, Recursion Pharm stock had its Relative Strength (RS) Rating upgraded to 84, up from 78 a day earlier.

Via Investor's Business Daily

Demystifying Recursion Pharmaceuticals: Insights From 4 Analyst Reviews ↗

May 10, 2024

Via Benzinga

(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest ↗

May 02, 2024

Via Benzinga

What's the Difference Between Biotech Stocks and TechBio Stocks? ↗

May 15, 2024

A few enterprising businesses are marketing themselves differently.

Via The Motley Fool

Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday ↗

May 14, 2024

Via Benzinga

The Next Drug You Take May be Designed By A.I.

May 14, 2024

Three stocks could give investors a better way to tap into A.I.'s future potential inside drug development, an industry that is set to grow at 29.6% until 2030

Via MarketBeat

Topics Artificial Intelligence

Recursion Pharmaceuticals Stock Surges 10% As Nvidia-Powered Supercomputer Completion Sparks Investor Optimism ↗

May 13, 2024

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) made waves Monday afternoon not only with the announcement of its groundbreaking BioHive-2 supercomputer but also with a notable surge in its stock...

Via Benzinga

Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week ↗

May 13, 2024

Via Talk Markets

Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

May 13, 2024

Via Benzinga

GameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday ↗

May 13, 2024

Via Benzinga

Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry

May 13, 2024

BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024.

From Recursion Pharmaceuticals

Via GlobeNewswire

Cathie Wood Is Buying This Under-the-Radar AI Stock ↗

May 12, 2024

This company has massive upside potential, but that's not the whole story.

Via The Motley Fool

Topics Artificial Intelligence

RXRX Stock Earnings: Recursion Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 ↗

May 09, 2024

RXRX stock results show that Recursion Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Nvidia-Backed Recursion Pharmaceuticals Stock Is Up On Q1 Earnings: Everything You Need To Know ↗

May 09, 2024

Recursion reported first-quarter revenue of $13.491 million, which beat analyst estimates of $12.65 million, according to Benzinga Pro. The company reported a quarterly loss of 39 cents per share,...

Via Benzinga

Nvidia Favorite SoundHound AI Delivers Beat-And-Raise Report ↗

May 09, 2024

SoundHound AI, which counts Nvidia as an investor, beat estimates for the first quarter and with its sales guidance. SOUN stock rose.

Via Investor's Business Daily

Topics Artificial Intelligence

Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results

May 09, 2024

From Recursion Pharmaceuticals

Via GlobeNewswire

Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May ↗

May 05, 2024

We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD.

Via Talk Markets

Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9

May 02, 2024

Company to host public L(earnings) Call on May 9 at 5:00 pm ET

From Recursion Pharmaceuticals

Via GlobeNewswire

Recursion to Participate in Upcoming Investor Conferences

May 01, 2024

From Recursion Pharmaceuticals

Via GlobeNewswire

Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program

April 30, 2024

The grant designates Altitude Lab as a top acceleration program for biotechnology startups

From Recursion Pharmaceuticals

Via GlobeNewswire

Nvidia Owns a 3.4% Stake in This Innovative Artificial Intelligence (AI) Stock Cathie Wood Loves ↗

April 27, 2024

The $50 million purchase could turn into Nvidia's biggest investment.

Via The Motley Fool

Topics Artificial Intelligence

The Top 3 Biotech Stocks to Buy in April 2024 ↗

April 27, 2024

Learn about the top three biotech stocks to take advantage of these companies' promising futures and pharmaceutical advances.

Via InvestorPlace

3 Millionaire-Maker Biotech Stocks ↗

April 25, 2024

The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential.

Via The Motley Fool

Jim Cramer Says This Energy Stock Is 'Terrific,' Calls Casey's General Stores A 'Winner' ↗

April 24, 2024

Cramer recommends selling PBR, buying EPD, LNG, RXRX, and CASY. Criticisms of AVGO's licensing changes dismissed. PBR and CASY stocks rise.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 24, 2024

Via Benzinga

Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week ↗

April 23, 2024

A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and...

Via Talk Markets

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.